自主登记与市场布局双轮驱动。目前，公司烯草酮、咪唑乙烟酸、异噁草松、烯酰吗啉等原药和制剂产 品，在主要目标市场的自主登记布局已全部完成，同时正在积极推动获批产品与客户的商务合作。在阿 根廷，公司成功获得2,4-滴丁酸丁酯、吡草醚制剂认证。独家产品氟吡酰草胺、2,4-滴丁酸在欧盟、澳 大利亚市场实现稳定供货，并在东南亚及中南美洲进入正式登记阶段。公司创制产品吡唑喹草酯、苯丙 草酮在美洲主要水稻主产国启动自主登记，药效反响良好，展现出巨大的商业潜力。 投资建议：公司专注高端除草剂产品开发，并形成了差异化的制剂证件优势，未来随着公司新的创制药 产品上市以及新项目陆续投产，公司业绩有望保持快速增长。考虑到公司烯草酮受市场供需关系影响售 价显著上涨，我们上调公司业绩预期，预计公司2025-2027 年归母净利润分别为2.34、2.99、3.70 亿 元，同比增速分别为+1005.31%、+27.66%、+23.75%，对应PE 分别为20X、15X、12X，维持"推荐"评 级。 稳步推进创制化合物的全产业链研发与产业化。公司专注于高端除草剂领域的科技创新和产品开发，截 至目前，公司拥有58 项发明专利，首款创制除草剂产 ...

Core Viewpoint - The company, Xian Da Co., Ltd. (603086.SH), is experiencing significant growth in its performance due to rising product prices and a strategic shift towards innovative product development, with a projected net profit increase of 24.43 to 28.35 times year-on-year for the first half of 2025 [1][2]. Group 1: Financial Performance - For the first half of 2025, the company expects a net profit between 130 million to 150 million yuan, marking a substantial increase compared to previous periods [1][2]. - In 2024, the company reported an operating income of 2.419 billion yuan, with a net loss of 25.8755 million yuan, which was a significant reduction in losses compared to 2023 [2]. - In Q1 2025, the company achieved an operating income of 543 million yuan, a year-on-year increase of 10.8%, and a net profit of 21.69 million yuan, successfully turning a profit [2]. Group 2: Product and Market Development - The main product, Acetochlor, has seen a price increase, with current market prices ranging from 120,000 to 160,000 yuan per ton, contributing to improved gross margins [3][4]. - The company has halted the expansion of homogeneous products and is focusing on innovative products, establishing a product matrix centered around Quinclorac, Pyrazosulfuron, and Benzoylpropionic acid [1][4]. - The company’s innovative herbicide Quinclorac has been promoted on over 2 million acres in 2024, with expectations to expand to 5 million acres in 2025 [4]. Group 3: Research and Development - The company has committed to a strategy of innovation-driven development, with total R&D expenses amounting to 559 million yuan from 2020 to 2024 [1][4]. - The company has developed a comprehensive innovation system covering synthesis, screening, pilot testing, and industrialization, with over 2,000 new compounds screened annually [4]. - The company plans to accelerate the global registration process for products like Pyrazosulfuron to strengthen its market position [6]. Group 4: Global Market Presence - The company’s products are sold in over 60 countries and regions, with overseas revenue accounting for 45% of total revenue [5]. - In 2024, the export volume of Acetochlor formulations increased by 88%, indicating strong competitive advantages in international markets [5].

Investment Rating - The report does not explicitly state the investment rating for Shandong Cynda Chemical Core Insights - The company's product volume and price have both increased, with the price of clethodim continuing to rise [1][4] - In Q1 2025, the company achieved a non-recurring net profit of 20 million yuan, a year-on-year increase of 224%, and an operating income of 543 million yuan, a year-on-year increase of 10.78% [2][3] - The gross profit margin was 17.78%, an increase of 4.97 percentage points year-on-year, while the net profit margin was 3.92%, an increase of 6.73 percentage points year-on-year [2][3] Summary by Sections Financial Performance - In Q1 2025, the total profit reached 24 million yuan, a year-on-year increase of 296.51%, and the net profit attributable to the parent company was 22 million yuan, a year-on-year increase of 257.63% [2][3] - The performance growth was driven by increased sales volume and price of major products [2][3] Market Conditions - The supply and demand in the market remain tight, with the mainstream transaction reference price of clethodim at 130,000 yuan per ton, an increase of 10,000 yuan per ton (up 8.33%) from the previous week [4] - Market spot inventory is low, and demand remains strong, with most enterprises able to schedule orders until July [4] Product Development - The company has made significant progress in original drug R&D, establishing a core matrix of innovative products including quinclorac, pyrazoxyfen, and Feproxydim [5] - The first original product, quinclorac, has been applied in over 2 million mu of sorghum fields, with rapidly growing sales [5] - The second original herbicide, pyrazoxyfen, is set to launch in 2025, while the third innovative herbicide, Feproxydim, is currently under review [5]

Core Viewpoint - The pesticide industry is gradually recovering after several years of downturn, with leading company XianDa achieving a turnaround in profitability in Q1 2025 [2][3]. Industry Recovery - The pesticide market in China saw 883 large-scale enterprises in 2024, a historical high, with total revenue increasing by 3.2% year-on-year, although total profit decreased by 3.4% [3]. - From September 2024, cumulative revenue began to show signs of recovery, indicating a gradual improvement in industry performance [3]. - XianDa reported a revenue of 2.419 billion yuan in 2024, with a net loss of 25.8755 million yuan, which was a significant reduction in losses compared to 2023 [3]. - In Q1 2025, XianDa achieved a revenue of 543 million yuan, a year-on-year increase of 10.8%, and a net profit of 21.69 million yuan, marking a successful turnaround [3]. Factors Contributing to Recovery - The industry has seen the elimination of outdated production capacity due to prolonged market stagnation, optimizing the supply-demand structure [4]. - The shift towards technology-driven transformation in Chinese pesticide companies, spurred by policy guidance, has provided new momentum for industry development [4]. Innovation as a Key Driver - Innovation has become a crucial lever for industry transformation, with 33 pesticide products recognized as patent-intensive in 2024, a year-on-year increase of 83.33%, and export value reaching 113.3 billion yuan [4]. - XianDa has increased its R&D investment to 4.6% of revenue, amounting to 111 million yuan in 2024, despite facing performance pressures [5][4]. - The company has established a comprehensive innovation system that enhances collaboration and risk management, significantly improving its R&D capabilities [6]. Management and Market Strategy - XianDa has adopted a "cylinder-shaped development model" to break down departmental barriers, fostering efficient collaboration among R&D, production, and marketing teams [8]. - The company has streamlined its product development cycle from 3-5 years to under 2 years through digital management systems [8]. - XianDa is focusing on creating innovative products, transitioning from selling raw materials to selling technology and leading market demand [9]. Global Market Expansion - XianDa aims to establish a strong presence in the global agricultural market, recognizing the need to enhance the international visibility of Chinese pesticide brands [10]. - The company is actively researching global pesticide registration policies to facilitate entry into high-end international markets [11]. - XianDa's products are currently sold in over 80 countries, with ambitions to build a globally influential Chinese agricultural brand [11].

Core Insights - The company reported a total revenue of 2.419 billion yuan for 2024, a year-on-year decrease of 1.68% [1] - The net profit attributable to shareholders was -26 million yuan, showing a year-on-year increase of 75.14% [1] - The company achieved a net profit of 22 million yuan in Q1 2025, marking a turnaround from losses [1] Group 1: Financial Performance - In Q4 2024, the company generated a revenue of 526 million yuan, a year-on-year increase of 32.93% but a quarter-on-quarter decrease of 15.14% [1] - The net profit for Q4 2024 was -32 million yuan, with a year-on-year increase of 72.02% but a significant quarter-on-quarter decline of 3072.19% [1] - For Q1 2025, the company reported a revenue of 543 million yuan, a year-on-year increase of 10.78% and a quarter-on-quarter increase of 3.10% [1] Group 2: Product Performance - The sales volume of the core product, Acetochlor, increased significantly, with exports rising by 88% in 2024 [2] - The total sales of Acetochlor reached 11,600 tons in 2024, a year-on-year increase of 56.9% [2] - In Q1 2025, Acetochlor sales continued to grow, reaching 2,326 tons, a year-on-year increase of 32.1% [2] Group 3: Innovation and Development - The company focuses on high-end herbicide product development, holding 58 invention patents as of December 31, 2024 [3] - The first innovative herbicide product, Quizalofop, was launched in 2021, and the second product, Pyrazolyl, was approved for registration in September 2024 [3] - The company aims to develop and commercialize a new innovative compound every two years [3] Group 4: Market Expansion and Projects - The company has successfully registered core products in key markets such as Brazil, the USA, and Argentina [4] - New production projects, including an annual capacity of 18,000 tons of pesticide raw materials, have been completed and are in trial production [4] - The company is enhancing its production capabilities to meet the growing domestic market demand [4] Group 5: Investment Outlook - The company is expected to maintain rapid growth in performance with new product launches and ongoing project developments [4] - Projected net profits for 2025-2027 are 102 million, 161 million, and 256 million yuan, with year-on-year growth rates of 495.98%, 57.23%, and 58.66% respectively [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a favorable outlook for investment over the next 6-12 months [7]. Core Insights - The company reported a significant improvement in performance for Q1 2025, with revenue of 543 million yuan, a year-on-year increase of 10.78% and a quarter-on-quarter increase of 3.10%. The net profit attributable to shareholders reached 22 million yuan, an increase of 3.55 million yuan year-on-year and 5.38% quarter-on-quarter [1][2]. - The company has successfully launched new herbicide products, with substantial market potential, particularly in high-value crops. The first product, Quizalofop, has been widely adopted, and additional products are set to launch in 2025 [3][4]. - The company is expanding its production capacity and has seen significant growth in overseas sales, particularly in key markets like Brazil and the United States [4]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 2.419 billion yuan, a slight decrease of 1.68% year-on-year, while the net profit attributable to shareholders improved by 0.78 billion yuan to a loss of 0.26 billion yuan. For Q1 2025, revenue was 543 million yuan, with a year-on-year increase of 10.78% and a quarter-on-quarter increase of 3.10% [1][2]. - The main products, including herbicides and fungicides, generated revenues of 2.219 billion yuan, 159 million yuan, and 34 million yuan respectively in 2024, with varying growth rates [2]. Product Development - The company is building a product matrix centered around innovative herbicides, with significant growth in sales since the launch of Quizalofop in 2021. The second product, Pyrazosulfuron, has received approval for market launch in 2025 [3]. - New projects for pesticide production are underway, with successful trials for new herbicides planned for registration in 2025 [4]. Market Expansion - The company has successfully launched production facilities that enhance its core raw material capacity, with significant growth in overseas sales, particularly for key products like Acetochlor, which saw an 88% increase in export volume [4]. - The company is actively pursuing registrations for its proprietary products in major international markets, enhancing its competitive position [4]. Profit Forecast and Valuation - The report adjusts profit forecasts for 2025-2026, estimating net profits of 89 million yuan and 194 million yuan respectively, while maintaining a positive outlook on capacity expansion and product registration progress [4].

中证报中证网讯(记者张鹏飞)4月22日晚间，先达股份（603086）发布2024年年度报告。报告显示，公 司全年实现营业收入24.19亿元，实现归母净利润为-2587.55万元，同比大幅减亏7822.72万元，减亏幅 度达73.57%。尽管农药行业面临价格低迷与需求疲软的双重压力，公司通过创新驱动与国内外市场协 同发展，经营业绩显著改善。公司同步披露的一季报显示，2025年一季度公司实现扭亏为盈，净利润达 2169.3万元。 创新创制成核心引擎多款产品产业化提速 海外市场方面，公司烯草酮制剂出口量同比激增88%，核心产品在巴西、美国、阿根廷等市场完成登 记，2,4-滴丁酸、氟吡酰草胺等独家产品海外订单逐步放量。创制化合物吡唑喹草酯、苯丙草酮在东南 亚、拉美等水稻主产区启动示范试验，药效反馈积极，为全球化布局奠定基础。 先达股份坚持创新驱动战略，聚焦高端除草剂领域，构建以喹草酮、吡唑喹草酯、苯丙草酮为核心的创 制化合物矩阵，形成差异化竞争力。 产能方面，新项目建设稳步推进，支撑公司长期发展。报告期内，辽宁基地一期至五期项目已成功投产 并实现产值，进一步巩固了公司在核心原药产能方面的优势。同时，公司新建"年产18 ...